Long term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

Ballmann, Manfred; Rabsch, Peter; von der Hardt, Horst
September 1998
Thorax;Sep1998, Vol. 53 Issue 9, p732
Academic Journal
No abstract available.


Related Articles

  • Mekonyum ileusunun 12 ay altında tanı alan kistik fibrozlu hastalarda klinik seyire etkisi. Pekcan, Sevgi; Kiper, Nural; Köse, Mehmet; Aslan, Ayşşe Tana; Çobanoğlu, Nazan; Yalçın, Ebru; Doğru, Deniz; Özçelik, Uğur // Turkish Pediatrics Archive / Turk Pediatri Arsivi;jun2010, Vol. 45 Issue 2, p105 

    Aim: Meconium ileus (MI) is an early clue to the diagnosis of cystic fibrosis (CF) and it occurs in about 15-20% of CF patients. To determine the possible prognostic factors in patients with cystic fibrosis with and without MI. Material and Method: The sample consisted of 214 patients with CF...

  • Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature. Marchetti, Federico; Giglio, Luisella; Candusso, Manila; Faraguna, Dino; Assael, Baroukh M. // European Journal of Clinical Pharmacology;Apr2004, Vol. 60 Issue 2, p67 

    Aim. To assess the evidence supporting early antibiotic treatment in asymptomatic cystic fibrosis (CF) patients colonised by Pseudomonas aeruginosa (PA). Methods. We carried out a computerised (Medline, Embase) and hand search of journals for suitable publications. All English-language clinical...

  • Macrolide antibiotics and cystic Fibrosis. Peckham, D. G. // Thorax;Mar2002, Vol. 57 Issue 3, p189 

    There is growing interest in the potential use of macrolide antibiotics as anti-inflammatory agents in cystic fibrosis. This stems from the dramatic success of long term erythromycin in the treatment of diffuse panbronchiolitis (DPB), a condition with a high prevalence in Japan but rare...

  • Aminoglycoside-Resistance Mechanisms for Cystic Fibrosis Pseudomonas aeruginosa Isolates Are... MacLeod, David L.; Nelson, Laura E.; Shawar, Ribhi M.; Lin, Betty B.; Lockwood, Luann G.; Dirks, Joy E.; Miller, George H.; Burns, Jane L.; Garber, Richard L. // Journal of Infectious Diseases;3/1/2000, Vol. 181 Issue 3, p1180 

    Tests the hypothesis that aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. Tobramycin-resistance mechanisms found in cystic fibrosis Pseudomonas aeruginosa isolates; Molecular...

  • Inhaled Tobramycin (TOBI®): A Review of its Use in the Management of Pseudomonas aeruginosa Infections in Patients with Cystic Fibrosis. Cheer, Susan M.; Waugh, John; Noble, Stuart // Drugs;2003, Vol. 63 Issue 22, p2501 

    Specifically formulated for nebulisation using the PARI LC PLUS™ reusable nebuliser, tobramycin solution for inhalation (TSI) [TOBI[sup ®]] provides a high dose of tobramycin (an aminoglycoside antibacterial with good activity against Pseudomonas aeruginosa) to the lungs of patients...

  • Effect of Chronic Intermittent Administration of Inhaled Tobramycin on Respiratory Microbial Flora in Patients with Cystic Fibrosis. Burns, Jane L.; Van Dalfsen, Jill M.; Shawar, Ribhi M.; Otto, Kelly L.; Garber, Richard L.; Quan, Joanne M.; Montgomery, A. Bruce; Albers, Gary M.; Ramsey, Bonnie W.; Smith, Arnold L. // Journal of Infectious Diseases;5/1/99, Vol. 179 Issue 5, p1190 

    Examines the effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. Effects of pseudomonas aeruginosa endobronchial infection; Patient population; Use of oral and parenteral antibiotics; Isolation of intrinsically...

  • Mucoid Pseudomonas aeruginosa and Cystic Fibrosis.  // Clinical Infectious Diseases;6/15/2005, Vol. 40 Issue 12, preceding p1 

    The article focuses on mucoid Pseudomonas aeruginosa and cystic fibrosis. The natural history of the acquisition of mucoid and nonmucoid strains of Pseudomonas aeruginosa in patients with cystic fibrosis was prospectively evaluated in 56 patients observed from birth to the age of 16 years. The...

  • Factors associated with reduced FEV1 in adult patients with cystic fibrosis in a relatively affluent area. Jarad, N. A.; Higgs, S.; Jeffcote, T.; Giles, K. // Chronic Respiratory Disease;2005, Vol. 2 Issue 3, p133 

    Data collected on adult cystic fibrosis (CF) patients and entered onto the CF database in the south and west regions of England were analysed for the year 2001. FEV1 was taken as a marker of lung disease severity. Data on 371 patients (158 female) mean age 24.7 years (range 16.0�48.9) were...

  • CLINIC ROUNDUP.  // BioWorld Today;6/21/2010, Vol. 21 Issue 118, p4 

    The article announces the accomplishment of one of the co-primary endpoints of noninferiority for mean percent change in forced expiratory volume in one second (FEV1) in the Phase III trial comparing the effectiveness of Cayston, aztreonam, from Gilead Sciences Inc. against the tobramycin...

  • TOBI Podhaler Approved.  // Monthly Prescribing Reference;May2013, Vol. 29 Issue 5, pA-26 

    The article informs that the tobramycin inhalation powder TOBI Podhaler from Novartis AG has been approved for treatment of cystic fibrosis in patients with Pseudomonas aeruginosa in lungs.


Read the Article


Sign out of this library

Other Topics